Literature DB >> 32476932

Sensitivity and specificity of chest imaging for sarcoidosis screening in patients with cardiac presentations.

Juan J Russo1, Pablo B Nery1, Andrew C Ha2, Jeff S Healey3, Daniel Juneau1, Lena Rivard4, Matthias G Friedrich5, Lorne Gula6, Gerald Wisenberg6,7, Robert deKemp1, Santabhanu Chakrabarti8, Tomasz W Hruczkowski9, Russell Quinn10, F Daniel Ramirez1, Girish Dwivedi1, Rob S B Beanlands1, David H Birnie1.   

Abstract

BACKGROUND: Patients with sarcoidosis can present with cardiac symptoms as the first manifestation of disease in any organ. In these patients, the use of chest imaging modalities may serve as an initial screening tool towards the diagnosis of sarcoidosis through identification of pulmonary/mediastinal involvement; however, the use of chest imaging for this purpose has not been well studied. We assessed the utility of different chest imaging modalities for initial screening for cardiac sarcoidosis (CS). METHODS AND
RESULTS: All patients were investigated with chest x-ray, chest computed tomography (CT) and/or cardiac/thorax magnetic resonance imaging (MRI). We then used the final diagnosis (CS versus no CS) and adjudicated imaging reports (normal versus abnormal) to calculate the sensitivity and specificity of individual and combinations of chest imaging modalities. We identified 44 patients (mean age 54 (±8) years, 35.4% female) and a diagnosis of CS was made in 18/44 patients (41%). The sensitivity and specificity for screening for sarcoidosis were 35% and 85% for chest x-ray, respectively (AUC 0.60; 95%CI 0.42-0.78; p value=0.27); 94% and 86% for chest CT (AUC 0.90; 95%CI 0.80-1.00; p value <0.001); 100% and 50% for cardiac/thorax MRI (AUC 0.75; 95%CI 0.56-0.94; p value=0.04).
CONCLUSIONS: During the initial diagnostic workup of patients with suspected CS, chest x-ray was suboptimal as a screening test. In contrast CT chest and cardiac/thorax MRI had excellent sensitivity. Chest CT has the highest specificity among imaging modalities. Cardiac/thorax MRI or chest CT could be used as an initial screening test, depending on local availability. Copyright:
© 2019.

Entities:  

Keywords:  cardiac sarcoidosis; cardiomyopathy; imaging; sarcoidosis; screening

Mesh:

Year:  2019        PMID: 32476932      PMCID: PMC7247116          DOI: 10.36141/svdld.v36i1.6865

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  17 in total

1.  Letter by Al-Kindi and Oliveira regarding article "cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study".

Authors:  Sadeer G Al-Kindi; Guilherme H Oliveira
Journal:  Circulation       Date:  2015-10-27       Impact factor: 29.690

2.  Canadian Society for Cardiovascular Magnetic Resonance (CanSCMR) recommendations for cardiovascular magnetic resonance image analysis and reporting.

Authors:  Matthias G Friedrich; Eric Larose; David Patton; Alexander Dick; Naeem Merchant; Ian Paterson
Journal:  Can J Cardiol       Date:  2012-09-23       Impact factor: 5.223

3.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.

Authors:  David H Birnie; William H Sauer; Frank Bogun; Joshua M Cooper; Daniel A Culver; Claire S Duvernoy; Marc A Judson; Jordana Kron; Davendra Mehta; Jens Cosedis Nielsen; Amit R Patel; Tohru Ohe; Pekka Raatikainen; Kyoko Soejima
Journal:  Heart Rhythm       Date:  2014-05-09       Impact factor: 6.343

4.  Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults.

Authors:  Pablo B Nery; Rob S Beanlands; Girish M Nair; Martin Green; Jim Yang; Brian A McArdle; Darryl Davis; Hiroshi Ohira; Michael H Gollob; Eugene Leung; Jeff S Healey; David H Birnie
Journal:  J Cardiovasc Electrophysiol       Date:  2014-05-02

5.  Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear.

Authors:  Binu Philips; Srinivasa Madhavan; Cynthia A James; Anneline S J M te Riele; Brittney Murray; Crystal Tichnell; Aditya Bhonsale; Saman Nazarian; Daniel P Judge; Hugh Calkins; Harikrishna Tandri; Alan Cheng
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-03-01

Review 6.  Cardiac Sarcoidosis.

Authors:  David H Birnie; Pablo B Nery; Andrew C Ha; Rob S B Beanlands
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

7.  Cardiac sarcoidosis underlies idiopathic dilated cardiomyopathy: importance of mediastinal lymphadenopathy in differential diagnosis.

Authors:  Kaoru Otsuka; Fumio Terasaki; Yoshinobu Eishi; Hiroaki Shimomura; Yasuharu Ogura; Taiko Horii; Tadashi Isomura; Hisayoshi Suma; Yasushi Kitaura
Journal:  Circ J       Date:  2007-12       Impact factor: 2.993

8.  Diagnosing cardiac sarcoidosis clinically without tissue confirmation.

Authors:  Poonam S Sharma; Jordon G Lubahn; Alan S Donsky; Anthony Dong H Yoon; Melissa M Carry; Paul A Grayburn; Prescilla Barrientos Wood; Jong Mi Ko; Elizabeth C Burton; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-07

9.  Uveitis with biopsy-proven sarcoidosis in Chinese--a study of 60 patients in a uveitis clinic over a period of 20 years.

Authors:  Yu-Mei Chung; Ying-Cheng Lin; Yin-Tzu Liu; Shi-Chuan Chang; Han-Nan Liu; Wen-Hu Hsu
Journal:  J Chin Med Assoc       Date:  2007-11       Impact factor: 2.743

10.  Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia.

Authors:  Pablo B Nery; Brian A Mc Ardle; Calum J Redpath; Eugene Leung; Robert Lemery; Robert Dekemp; Jim Yang; Arieh Keren; Rob S Beanlands; David H Birnie
Journal:  Pacing Clin Electrophysiol       Date:  2013-09-17       Impact factor: 1.976

View more
  1 in total

1.  Sarcoidosis: a prospective observational cohort from Northern Alberta.

Authors:  Dilini Vethanayagam; Jillian Peters; Emad Saad; Kimberley Mulchey; Ashley-Mae Gillson; Brian McNab; Maxine Farr-Jones; Tomasz Hruczkowski; Gregg Blevins; Richard Coulden; Gavin Oudit; Jeremy Beach
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-12-16       Impact factor: 0.670

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.